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Abstract
Background: Healthy condition and chronic diseases may be associated with microbiota composition and its
properties. The prevalence of respiratory haemophili with respect to their phenotypes including the ability to
biofilm formation in patients with sarcoidosis was assayed.
Methods: Nasopharynx and sputum specimens were taken in 31 patients with sarcoidosis (average age 42.6 ± 13),
and nasopharynx specimens were taken in 37 healthy people (average age 44.6 ± 11.6). Haemophili were identified
by API-NH microtest and by the matrix-assisted laser desorption/ionization time-of-flight mass spectrometry
(MALDI-TOF MS) system. Biofilm was visualised by crystal violet staining and confocal scanning laser microscopy
(CSLM). The statistical analysis was performed with Statgraphics Plus for Windows.
Results: In total, 30/31 patients with sarcoidosis and 31/37 healthy people were colonized by Haemophilus influenzae
(6/30 vs. 1/31) and Haemophilus parainfluenzae (28/30 vs. 31/31) in the nasopharynx. The overall number of nasopharyngeal
haemophili isolates was 59 in patients with sarcoidosis and 67 in healthy volunteers (H. influenzae 6/59 vs. 1/67, P = 0.05; H.
parainfluenzae 47/59 vs. 65/67, P = 0.0032). Moreover, the decreased number of H. parainfluenzae biofilm-producing isolates
was shown in nasopharyngeal samples in patients with sarcoidosis as compared to healthy people (19/31 vs. 57/65, P = 0.
006), especially with respect to isolates classified as strong and very strong biofilm-producers (8/31 vs. 39/65, P = 0.002).
Conclusions: The obtained data suggest that the qualitative and quantitative changes within the respiratory microbiota
concerning the overall prevalence of H. influenzae together with the decreased number of H. parainfluenzae strains and the
decreased rate of H. parainfluenzae biofilm-producing isolates as compared to healthy people may be associated with
sarcoidosis.
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Background
Sarcoidosis is a chronic and enigmatic multisystem dis-
ease involving the lung, heart and the lymphatic system
[1, 2]. The etiology of sarcoidosis is not likely to be due
to any infections, but rather to an exaggerated and aber-
rant immune response of genetically susceptible individ-
uals to unidentified antigens, including microorganisms,
or several organic and inorganic substances [1–4].
Understanding the role of microbiota composition is a
new frontier of human biology and the contemporary dir-
ection in the investigation of physiological or pathological
phenomena of health or diseases [5–7]. Qualitative and
quantitative shifts or perturbation in the microbiota can
lead to the development of diseases. Microbiota monitor-
ing and modification may be useful for determination of
health, thus providing new means of protection and/or of
intervention, and data interpretation [8–10]. The micro-
biota components predominantly colonizing the respira-
tory mucosa without causing any disease symptoms can
occasionally cause respiratory infections. Besides possible
positive or negative interactions between commensals and
pathobionts as well as other potential pathogens, micro-
biota can play an important role for the human host
organism in preventing of respiratory and invasive infec-
tions [11]. Additionally, microbiota disturbance can con-
tribute to acquisition and carriage of pathogens, can
predispose to viral co-infection, especially in people with
an immature or damaged immune system.
The human-restricted respiratory tract microbiota rep-
resentatives are Haemophilus influenzae with significant
pathogenicity and opportunistic commensal H. parain-
fluenzae [12, 13]. They may be etiologic agents of
invasive or opportunistic diseases [14–16]. H. influenzae,
both the encapsulated (mainly serotype b – Hib) and
non-encapsulated (nontypeable H. influenzae - NTHi)
strains have also been associated as potential pathogens
with chronic or recurrent and invasive diseases (e.g.
bacteremia or sepsis, otitis media, chronic bronchitis,
and community-acquired pneumonia) often reported in
children and rarely in adults. H. parainfluenzae, as an
opportunistic bacteria, less often reported as an etiologic
agent of infectious diseases, may cause systemic or other
respiratory infections (e.g. epiglottitis, meningitis,
bacteremia or sepsis, bronchitis, chronic obstructive
pulmonary disease, and infective endocarditis).
The human microbiota is a reservoir of opportunistic
and potential pathogens (pathobionts), including haemo-
phili, living mainly in a diverse community of biofilm
[17–19]. Biofilm as a structure of microbial community
enveloped in a polymeric matrix and adhered to both nat-
ural and synthetic surfaces may be regarded as a pheno-
typic adaptation and protective or pathogenic factor in
many infections, depending on the condition [11, 20–22].
It was found to be a form of microbial life important both
in colonization and in chronic and recurrent or acute dis-
eases such as otitis media and pneumonia caused by
NTHi species [17]. Biofilm is estimated to be involved in
about 65 % of human infections with bacterial etiology
[23]. Adhesive properties, as well as biofilm formation by
microoorganisms together with its intrinsic antimicrobial
resistance, exopolysaccharide production and quorum
sensing are factors allowing for adaptation to host organ-
ism [20]. Both H. influenzae and H. parainfluenzae have
been found to be a biofilm-forming bacteria.
The objectives of the present study were: the analysis
of the correlations of diagnostic results in patients with
sarcoidosis based on simple regression, haemophili isola-
tion in nasopharyngeal and sputum specimens, anti-
microbial resistance determination in H. influenzae and
H. parainfluenzae clinical isolates, biofilm production by
clinical isolates of these species together with the ana-
lysis of its structure.
Methods
Patients
A group of 31 adult patients (average age 42.6 ± 13) with a
suspicion of sarcoidosis who were diagnosed in 2011 at the
Chair and Department of Thoracic Surgery (Medical Uni-
versity of Lublin, Poland), participated in the study. The se-
lection criterion was sarcoidosis, which was diagnosed
with clinical findings suggesting an incidence of this dis-
ease. Patients were directed for diagnosis because of radio-
logical findings such as: lymphadenectomy or tumour of
mediastinum, or the presence of small nodules and infiltra-
tions in the lung parenchyma, sclerosis, thickening or fi-
brosis discovered in CT scans. Multivariable demographic,
clinical, radiographic and histological data were collected
on the basis of the patients’ questionnaires and informa-
tion protocol.
All patients were diagnosed by means of bronchoscopy,
mediastinoscopy or/and lung biopsy. Before the procedure
blood samples were collected for standard blood tests
(basic metabolic panel and complete blood count). The
obtained tissue samples were evaluated by the same
pathomorphologist. The histopathological findings were
usually described as tuberculosis like granulation which
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could be considered as sarcoidosis in accordance with
clinical changes.
A control group of 37 healthy volunteers (average age
44.6 ± 11.6) who agreed to participate in the survey was
also included. They did not suffer from respiratory infec-
tions and had not received an antimicrobial therapy for
at least three months prior to the examination or had
not been admitted to hospital for at least two years.
Written informed consent for participation was ob-
tained from people who agreed to take part in the study
and filled out the survey. The Ethics Committee of the
Medical University of Lublin approved study protocol
(KE-0254/75/2011).
Microbiological processing of haemophili isolates
A total of 31 nasopharyngeal swabs and 31 sputum speci-
mens were taken from patients with sarcoidosis on the
day of hospitalization or a day after. Additionally, 37 naso-
pharyngeal specimens were collected from healthy people.
After incubation (48 h, 35 ± 2 °C, 5 % CO2) the colonies
with morphological differences were identified independ-
ently on selective HAEM-medium (Haemophilus-choc-
olate-agar, bioMérieux, France). The growth of bacteria in
the form of individual colonies or from abundant to very
abundant number of morphologically different colonies
on Chocolate agar was observed. Initially biochemical
identification and biotyping of 192 Gram-negative isolates
(125 – from patients with sarcoidosis and 67 – from
healthy people) was carried out using the API-NH microt-
est (bioMérieux). The phenotypes of haemophili isolates
were differentiated based on various observable properties
in the growth morphology (e.g. the shape and size of the
colony, smooth or rough surface, texture, colony
elevation), on a set of biochemical reactions (according to
API NH results) and antimicrobial susceptibility results.
API-NH is a standardized system for the identification of
Neisseria, Haemophilus (and related genera) and Morax-
ella (B.) catarrhalis, which uses microtests and a specially
adapted database. Next, for the species differentiation the
matrix-assisted laser desorption/ionization time-of-flight
mass spectrometry (MALDI-TOF MS, Bruker Daltonik,
Germany) system was used according to the procedure
described earlier [24]. Software used for data acquisition
was MALDI-Biotyper 3.0 (Bruker Daltonik) software. The
species which were not identified as H. influenzae or H.
parainfluenzae were classified as other Haemophilus spp.
Antibiotic sensitivities were determined by the disc
diffusion method using Haemophilus-Test-Medium
(HTM, Oxoid) according to [25]. Direct colony suspen-
sions standardized to 0.5 McFarland standard were pre-
pared using colonies from an overnight HAEM
incubation (35 °C, 5 % CO2). H. influenzae ATCC10211
was used to verify the growth of bacteria on HTM
medium. Different discs with antimicrobial agents (BD
BBL™, Becton Dickinson and Company, USA) namely
ampicillin 10 μg, amoxicillin/clavulanate 20/10 μg, ampi-
cillin/sulbactam 10/10 μg, cefuroxime 30 μg, cefotaxime
30 μg, ceftazidime 30 μg, imipenem 10 μg, aztreoname
30 μg, azithromycin 15 μg, tetracycline 30 μg, trimetho-
prim/sulfamethoxazole 1.25/23.75 μg, ciprofloxacin 5 μg
were used. Resistance (R) zone diameter interpretative cri-
teria were ≤18 mm for ampicillin, ≤19 mm for amoxicillin-
clavulanate and ampicillin-sulbactam, ≤16 mm for cefurox-
ime, ≤25 mm for cefotaxime and ceftazidime, ≤15 mm for
imipenem, ≤ 25 mm for aztreoname, ≤11 mm for azithro-
mycin, ≤25 mm for tetracycline, ≤10 mm for trimethoprim/
sulfamethoxazole, ≤20 mm for ciprofloxacin, according to
[25]. Multidrug-resistant (MDR) isolates were defined as
having resistance to at least three different classes of anti-
microbials. Beta-lactamase activity was screened by Pen-
microtest (part of API-NH strip) and confirmed with a
nitrocefin-based test (Cefinase™-Discs, BD BBL™) recom-
mended for testing haemophili [25]. Then, E-test strips
(bioMérieux) for a determination of susceptibility on the
basis of the minimal inhibitory concentration of ampicillin
(MICAm) were used. The MIC criterion, defined as the low-
est concentration of the antimicrobial agent that prevents
visible growth of the microorganism, for ampicillin-resitant
haemophili was ≥ 4 μg/ml [25].
Biofilm detection
Biofilm formation was examined during the stationary cul-
ture in vitro in 24-well polystyrene microplates (24 F-Well
Microplates, Thermo Scientific™ Nunc™, Denmark) using a
0.1 % crystal violet (CV) stain as previously described [26].
The Tripticasein Soy Broth (TSB, Biocorp, Poland) supple-
mented with Haemophilus Test-Medium Supplement
(HTMS, Oxoid) designated as TSB +HTMS was used.
Overnight cultures were diluted in TSB +HTMS-medium
and standardized at 570 nm with an initial optical density
of OD570 ~ 0.08 ± 0.02 (~0.5 McFarland-standard) using a
microplate reader ELx800 (BioTek Inc., USA). Next,
500 μl of the microbial suspension was inoculated for each
well and incubated (35 °C, 24 h, 5 % CO2). The growth of
haemophili was assessed by measuring the OD570. Nonad-
herent cells were removed by rinsing the wells with sterile
water. The biofilm was detected with OD570 according to
the method based on staining with 500 μl 0.1 % CV. Each
isolate was tested in triplicate in three series. TSB +
HTMS without bacteria was incubated under the same
conditions and served as blank control.
Haemophili were classified as biofilm-producers as de-
scribed elsewhere [26]. The experiments were performed
in triplicate and the results were averaged. For the pur-
poses of a detailed analysis of the obtained results the
classification of biofilm producers was introduced on the
basis of criteria proposed by Stepanović et al. [27] and
modified by Kosikowska et al. [26]. They defined the
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cut-off an optic density OD (ODc) for the microtiter-
plate test as three standard deviations above the mean
OD of the negative control. The bacteria were classi-
fied as follows: OD ≤ODc - non-producers (category
0); ODc < OD ≤ 2 x ODc - weak producers (category
1); 2 x ODc < OD ≤ 4 x ODc – moderate producers
(category 2); 4 x ODc <OD ≤ 8 x ODc – strong producers
(category 3), 8 x ODc <OD – very strong producers
(category 4). ODc was 0.1 ± 0.02 in our experiments. Add-
itionally, H. influenzae ATCC10211, H. parainfluenzae
ATCC7901, H. parainfluenzae ATCC33392 and H. para-
influenzae ATCC51505 reference strains were used as bio-
film producers. All tests were carried out three times and
the results were averaged.
To visualize H. influenzae and H. parainfluenzae
biofilm formation in a 24 h culture in 24-well polystyr-
ene microplates, the inverted microscope Axiovert
200 M equipped with LSM5 Pascal Head (Carl Zeiss,
Germany, with magnification 200×) was used. To obtain
images of the biofilm, cultures were stained with Bacter-
ial Live/Dead® BacLight™-L7012-kit (Invitrogen, USA) ac-
cordingly to the manufacturer’s procedure. Biofilm was
stained with Live/Dead® L7012 kit with two components,
Syto9 and propidium iodide (PI), which are nucleic acid
stains. The Syto9 stain penetrates through the intact and
damaged cell wall, intercalates into DNA, and emits
green fluorescence (detection of both live and dead bac-
teria). The PI stain diffuses only across the dead and
damaged cell wall, intercalates into DNA and emits red
fluorescence (detection of dead bacteria). The use of a
combination of these two dyes is that PI displaces Syto9
(it had a higher affinity) reducing its fluorescence. Thus,
the bacteria with intact cell membranes stain fluorescent
green, whereas with damaged cell membranes stain
fluorescent red. Biofilm formation by 7H. influenzae
and 18H. parainfluenzae randomly selected clinical iso-
lates taken in patients with sarcoidosis was screened
using confocal microscopy. The thickness of biofilm
(μm) and measurement area covered by biofilm (%),
content of live cells (%) and biofilm area covered by live
cells (%) were detected.
Overnight cultures were standardized in TSB +HTMS-
medium. Then 500 μl/well of cultures was added (for each
strain in quadruplicate). After incubation (35 °C, 24 h, 5 %
CO2) the content of the wells was removed and each well
was washed three-four times with 0.85 % NaCl. Then,
500 μl/well of 0.85 % NaCl was added and then stained
with 1.5 μl of Live/Dead-kit solution. Microphotographs
were taken in the green and/or red channel in a Confocal
Laser Scanning Microscope LSM5-PASCAL (CLSM; Carl
Zeiss, Germany) after incubation for 15 min in the dark at
room temperature. This experiment was repeated twice.
The planimetric measurement of the biofilm was per-
formed based on the microphotographs taken at 50× or
200× magnification in a two-dimensional scan (2D). Bio-
film parameters were calculated using ImageJ-1.43e soft-
ware (Wayne Rasband, National Institutes of Health,
USA). A three-dimensional (3D) image of biofilm was
reconstructed using the CLSM (200× magnification).
Statistical analysis
The statistical analysis was performed with Statgraphics
Plus for Windows, Version 4.1 (Statistical Graphics Corp.
1999, Statpoint Technologies, Inc. Warrenton, Virginia,
USA). To assess the relationship between the variables a
simple regression analysis was used. The aim of the statis-
tical analysis was preliminary determination of the rela-
tionship between individual factors and the dependent
variables. The relationship between age/gender and differ-
ent clinical manifestations and laboratory findings were
studied. The hypotheses were raised: H0 - there is no asso-
ciation between age/gender and different clinical manifes-
tations and laboratory findings, and H1 - there is an
association between age/gender and different clinical
manifestations and laboratory findings. Quantitative vari-
ables were presented as mean (± standard deviation, SD)
and median values. In some studies Fisher’s test was evalu-




The main characteristics of patients with sarcoidosis are
summarized in Table 1. Demographic and clinical data
were obtained from the patients’ files and based on a
questionnaire conducted for the presented variables.
“Fatigue” was self reported as being unable to go any
further. Susceptibility to “fatigue” was associated with a
short walk on a flat surface, or with stair walk to the first
or second floors. Symptoms such as shortness of breath,
wheezing, cough, expectoration, hypertension, coronary
artery disease, allergy, asthma, and recurrent infections
(≥3/year) were also considered. Almost 26 % of the pa-
tients with sarcoidosis showed recurrent infections in
childhood and had other symptoms such as anaemia, ce-
liac disease, or endocrinological disorders. Some of them
had two parallel disorders, for example hypertension and
coronary artery disease (about 13 %), and/or allergy
(about 10 %).
There was a positive correlation (P < 0.1) between gender
and a tumor of the lung/mediastinum (c = 0.4) or fluid in
the pleural cavity (c = 0.32) in patients with sarcoidosis
(Table 2). These changes mostly occurred in males rather
than in females. A positive correlation was demonstrated
between gender and CRP (C-reactive protein; P = 0.01, c =
0.44), and in elderly patients between the disease and visible
changes (e.g. sclerosis, thickening or fibrosis) in the imaging
diagnostics of the chest (P < 0.1, c = 0.34–0.45). A negative
Kosikowska et al. BMC Infectious Diseases  (2016) 16:449 Page 4 of 13
correlation between age and IgM (P < 0.1, c = -0.4) values
was detected. Besides, changes in levels of IgG and IgA im-
munoglobulins were observed.
The prevalence of haemophili-positive clinical samples
In total, 30/31 (96.8 %) patients with sarcoidosis were
colonized by H. influenzae and/or H. parainfluenzae. H.
influenzae was isolated in 14/30 (46.7 %) patients - in 1/
14 (7.1 %) only in nasopharynx, in 8/14 (57.1 %) only in
the sputum and in 5/14 (35.7 %) patients in both sam-
ples (Fig. 1a). H. parainfluenzae was isolated in 30/30
(100 %) patients - in 2/30 (6.7 %) only in nasopharynx,
in 2/30 (6.7 %) only in the sputum and in 26/30 (86.6 %)
cases in both samples (Fig. 1b). The co-existence of H.
influenzae and H. parainfluenzae was found in 14/30
(46.7 %) patients.
In comparison, nasopharynx in 31/37 (83.8 %) of
healthy people was colonized by both species: in 1/31
(3.2 %) - by H. influenzae, in 31/31 (100 %) - by H. para-
influenzae. There were significant differences in the fre-
quency of nasopharynx colonization by H. influenzae (P
= 0.05), but not by H. parainfluenzae (P = 0.49) in pa-
tients with sarcoidosis and in healthy people.
Negative correlations (a simple regression) were found
between H. influenzae presence in the sputum and O2 sat-
uration (P < 0.01, c = -0.52) or easily bleeding capillaries
(P < 0.05, c = -0.53), and between H. influenzae presence
both in the nasopharynx and in the sputum and the scler-
otic changes in lung (P < 0.05, c = -0.4 and c = -0.44, re-
spectively). Positive correlations were found between H.
parainfluenzae isolation in the sputum and the presence
of fluid in the pleural cavity (P < 0.01, c = 0.56), pH value
(P < 0.05, c = 0.39), or O2 saturation (P < 0.1, c = 0.32) and
tuberculosis like findings (P < 0.1, c = 0.35). Negative
correlations were found between H. parainfluenzae
isolation in the sputum and FVC (Forced Vital Capacity;
P < 0.1, c = -0.35).
Number of haemophili isolates
From one to six different phenotypes of haemophili were
isolated in the nasopharynx and/or in the sputum
Table 1 Baseline clinical characteristics, laboratory findings, and
predisposing factors in the group of patients with sarcoidosis




















a short walk (n = 1) 1/22 4.5
1st floor (n = 4) 4/22 18.2
2nd floor (n = 17) 17/22 77.3
Hypertension, coronary artery disease 4/31 12.9
Allergy 3/31 9.7
Asthma 1/31 3.2
Recurrent infection (≥3/year) 1/31 3.2
Recurrent infections in childhood 8/31 25.8





FVC (ml) 2740–6200 4208.1 ± 883.2
FEV1 (ml) 1600–5050 3231 ± 810.3
FEV1/FVC% 58–95 76.5 ± 8.7
pH 7.35–7.49 7.43 ± 0.03
pO2 (mmHg) 63.2–108 82.6 ± 10.5
pCO2 (mmHg) 32.8–49.1 95.4 ± 2.7
Saturation (%) 90.9–97.3 95.4 ± 1.8
IgG (g/l, reference: 7.0–16.0) 7.1–21.6 10.8 ± 2.7
IgM (g/l, reference: 0.4–2.3) 0.28–3.54 1.38 ± 0.8
IgA (g/l, reference: 0.7–4.0) 0.51–6.9 2.57 ± 1.3
CRP (mg/l, reference: 0.0–5.0): 0.51–80.48 7.23 ± 16.7
0.0–5.0 (n = 25) 0.51–4.15 1.51 ± 0.93
5.1–80.48 (n = 6) 5.8–80.48 31.10 ± 28.83
Table 1 Baseline clinical characteristics, laboratory findings, and
predisposing factors in the group of patients with sarcoidosis
(Continued)
Changes in CT scan 30/30 100




Data were presented as: No. of positive samples/No. of examinations or value
range; mean ± SD
Abbreviations: CT computed tomography, CRP C-reactive protein, FEV1 forced
expiratory volume in one second, FVC forced vital capacity, IgA, IgM, IgG
immunoglobulin A, M, G, NP nasopharynx, SP sputum; susceptibility to “fatigue”
was associated with a short walk on a flat surface, or with stair walk to the first or
second floors. “Fatigue” was self reported as being unable to go any further
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samples in each single patient. The growth morphology
and biochemical features distinguished phenotypes of
isolates. In total, 125 haemophili isolates were found in
62 nasopharyngeal swabs and sputum samples obtained
in patients with sarcoidosis. In 30 haemophili-positive
nasopharyngeal samples 59/125 (47.2 %) isolates were
identified: 6/59 (10.2 %) as H. influenzae, 47/59 (79.7 %)
as H. parainfluenzae and 6/59 (10.2 %) as other Haemoph-
ilus spp. In 30 haemophili-positive samples taken in the
sputum, 66/125 (52.8 %) isolates were identified: 13/66
(19.7 %) as H. influenzae, 49/66 (74.2 %) as H. parain-
fluenzae and 4/66 (6.1 %) as other Haemophilus spp.
Likewise, in 31 haemophili-positive samples obtained
in the nasopharynx of healthy people 67 isolates were
identified: 1/67 (1.5 %) as H. influenzae, 65/67 (97.0 %)
as H. parainfluenzae, and 1/67 (1.5 %) as other
Haemophilus spp. H. parainfluenzae was the main spe-
cies isolated from the nasopharynx in both groups.
There were statistically significant differences between
the number of H. influenzae (P = 0.05) or H. parain-
fluenzae (P = 0.0032) isolates in patients with sarcoidosis
and in healthy people.
Biotypes of H. influenzae and H. parainfluenzae isolates
A total of 19H. influenzae and 96H. parainfluenzae
strains isolated from patients with sarcoidosis were
assigned to eight biotypes. Biotypes III and VI occurred
in 47.4 % and 26.3 %H. influenzae isolates respectively,
mainly in the sputum (Table 3). Biotypes I (60.4 %) and
II (30.2 %) constituted most of the H. parainfluenzae
isolates both in the nasopharynx and in the sputum. For
comparison, thedifferences were observed in nasopha-
ryngeal H. parainfluenzae biotypes I-IV identified in
healthy people and in patients with sarcoidosis (biotype
I: 58.5 % vs. 26 %, P = 0.6998; biotype II: 20 % vs. 16 %,
P = 0.1864; biotype III: 12.3 % vs. 5.2 %, P = 1.000 and
biotype IV: 6.2 % vs. 1 %, P = 0.397, respectively).
Antimicrobials sensitivity of H. influenzae and H.
parainfluenzae isolates
As shown in Table 4, only 4/19 (21.1 %) H. influenzae
isolates from patients with sarcoidosis were resistant to
the antimicrobials - 2/19 (10.5 %) were trimethoprim/
sulfamethoxazole-resistant and 2/19 (10.5 %) were
tetracycline-resistant (Table 4). In contrast, 53/96
(55.2 %) H. parainfluenzae isolates were resistant to the
antimicrobials – 18/96 (18.8 %) were trimethoprim/
sulfamethoxazole-resistant and 15/96 (15.6 %) were
tetracycline-resistant. In addition, 20/96 (20.9 %) H.
parainfluenzae isolates were resistant to beta-lactams,
including 8/96 (8.3 %) ampicillin-resistant ones.
The presence of nasopharyngeal H. parainfluenzae iso-
lates resistant to tetracycline (4/65; 6.2 %) and to tri-
methoprim/sulfametoxazole (8/65; 12.3 %) was shown in
Table 2 Patient characteristics by age and gender correlations with clinical conditions, laboratory findings, and complications
Tests Test results Age (years) Gender
P value Correlation P value Correlation
Clinical manifestation Sclerotic changes in lung 0.84 0.04 0.64 0.09
Enlargement of the mediastinal lymph nodes 0.45 −0.14 0.9 0.02
Tuberculosis like findings 0.23 0.23 0.23 0.23
Chest radiography Micronodules 0.81 −0.05 0.63 0.12
Pulmonary shading/infiltrations 0.05 0.45* 0.28 −0.26
Tumor of the lung/mediastinum 0.36 0.22 0.08 0.4*
Chest CT Changes sclerosis/thickening/fibrosis 0.61 0.22 0.64 0.04
Lymphadenopathy 0.06 0.34* 0.16 −0.27
Fluid in the pleural cavity 0.44 0.15 0.09 0.32*
Changes observed during bronchofiberoscopy Infiltration of bronchial wall/macrophages 0.38 0.23 0.66 −0.12
Scraps of bronchial epithelial/mucus 0.28 0.28 0.39 0.22
Easy bleeding capillaries 0.17 −0.35 0.33 0.25
Laboratory findings pH 0.77 −0.06 0.68 −0.08
IgG (g/l) 0.74 −0.06 0.41 0.15
IgM (g/l) 0.25 −0.4* 0.27 −0.2
IgA (g/l) 0.17 0.25 0.47 0.14
CRP (mg/l) 0.21 0.23 0.01 0.44**
Abbreviations: CT computed tomography, CRP C-reactive protein
The significance levels were marked as: *P < 0.1, and **P < 0.05)
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healthy people. In addition, 23/65 (35.4 %) isolates were
resistant to beta-lactams, including 10/65 (15.4 %)
ampicillin-resistant ones.
The difference in presence of nasopharyngeal H.
parainfluenzae isolates resistant to tetracycline in pa-
tients with sarcoidosis and in healthy people (19.1 % vs.
6.2 %, P = 0.041) was statistically significant. The differ-
ences in resistance to trimethoprim/sulfametoxazole
(21.3 % vs. 12.3 %, P = 0.297) and to beta-lactams
(23.4 % vs. 35.3 %, P = 0.214), including ampicillin
(12.8 % vs. 15.4 %, P = 1.000) were also found, but they
were not statistically significant.
The ampicillin-resistant isolates selected in patients with
sarcoidosis (MICAm ≥ 6 μg/ml) were beta-lactamase-
positive, and were found within I and III biotypes (Table 5).
High MICs for ampicillin were detected in two isolates
taken in the nasopharynx (MIC = 128 and >256 μg/ml),
and in one isolate taken in the sputum (MIC = 48 μg/ml).
Among H. parainfluenzae isolates, 3/96 (3.1 %) isolates
were resistant to beta-lactams, tetracycline, and trimetho-
prim/sulfametoxazole (MDR-strains).
Biofilm formation by H. influenzae and H. parainfluenzae
isolates
In total, 69 randomly selected H. influenzae and H. parain-
fluenzae isolates (35 - nasopharyngeal, 34 - from the spu-
tum) taken in patients with sarcoidosis were screened for
biofilm-production using the CV method. According to
Table 6, 8/12 (66.7 %) isolates of H. influenzae and 39/57
(68.4 %) of H. parainfluenzae were found to be biofilm-
producers (P= 0.407). All 8/12 (66.7 %) H. influenzae
isolates were weak-producers, irrespective of the clinical
specimens. Among 19 biofilm-forming H. parainfluenzae
isolates from nasopharynx, the ability to biofilm formation
ranged from weak (11/19, 57.8 %) to strong (1/19, 5.3 %)
and very strong (7/19, 36.8 %).
Additionally, reference strains were included as biofilm-
producers: H. influenzae ATCC10211as weak biofilm-
producer (OD570 = 0.098 ± 0.05), H. parainfluenzae ATCC
7901 as strong biofilm-producer (OD570 = 0.682 ± 0.07), and
both H. parainfluenzae ATCC33392 and H. parainfluenzae
ATCC51505 as very strong biofilm-producers (OD570 =
1.191 ± 0.04 and OD570 = 1.026 ± 0.08, respectively).
Fig. 1 The prevalence of Haemophilus influenzae (a) and Haemophilus parainfluenzae (b) positive clinical samples in patients with sarcoidosis
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In 65H. parainfluenzae isolates obtained from naso-
pharynx of healthy people, in 57/65 (87.7 %) isolates the
ability for biofilm formation was identified (Table 6).
Among 57 biofilm-positive H. parainfluenzae isolates 15/
57 (26.3 %), 3/57 (5.3 %), 12/57 (21.1 %), and 27/57
(47.4 %) ones were classified as weak, moderate, strong or
very strong biofilm-producers, respectively. Significant dif-
ferences between the ability to biofilm production in naso-
pharyngeal H. parainfluenzae isolates taken in patients
with sarcoidosis and in healthy people were shown (P =
0.006). Among biofilm-positive H. parainfluenzae isolates
taken in cases and in healthy people significant differences
were observed between weak biofilm-producers and the
group of isolates classified as moderate, strong and very
strong biofilm-producers (P = 0.024).
Morphometric parameters of biofilm formed by 7H.
influenzae and 18H. parainfluenzae isolates taken from
the patients with sarcoidosis were assessed by means of
CLSM technique (Table 7). The biofilm formed by H.
influenzae isolates had the thickness of 14.2 ± 3.5 μm
and covered 71.6 ± 5.6 % of the measured area. The con-
tent of living cells was from 8.6 to 95.2 % (average 71.6
± 4.4 %) and it was 75.2 ± 4.8 % in the biofilm area. The
biofilm formed by H. parainfluenzae isolates had the
thickness of 20.02 ± 4.3 μm and covered about 50.6 ±
4.8 % of the measured area. The content of living cells
was from 42.8 to 99.9 % (average 80.9 ± 4.8 %) and it
was about 77.9 ± 8.98 % in the biofilm area.
The biofilm formed by one of H. parainfluenzae naso-
pharyngeal isolate taken from a patient with sarcoidosis
Table 3 Distribution of Haemophilus influenzae and Haemophilus parainfluenzae biotypes in healthy people and in patients with sarcoidosis
Healthy people Patients with sarcoidosis
Biotype Nasopharynx Nasopharynx Sputum Total
No. (%) of isolates
Haemophilus influenzae n = 1 n = 19
II 0 (0) 3 (15.8) 0 (0) 3 (15.8)
III 0 (0) 2 (10.5) 7 (36.8) 9 (47.4)
VI 1 (100) 1 (5.3) 4 (21.1) 5 (26.3)
VIII 0 (0) 0 (0) 2 (10.5) 2 (10.5)
Haemophilus parainfluenzae n = 65 n = 96
I 38 (58.5) 25 (26.0) 33 (34.4) 58 (60.4)
II 13 (20.0) 15 (15.6) 14 (14.6) 29 (30.2)
III 8 (12.3) 5 (5.2) 1 (1.04) 6 (6.3)
IV 4 (6.2) 1 (1.04) 0 (0) 1 (1.04)
VI 1 (1.5) 1 (1.04) 0 (0) 1 (1.04)
VII 0 (0) 0 (0) 1 (1.04) 1 (1.04)
VIII 1 (1.5) 0 (0) 0 (0) 0 (0)
Table 4 Distribution of antimicrobial resistance in Haemophilus influenzae and Haemophilus parainfluenzae isolates in healthy people
and in patients with sarcoidosis
No. (%) of resistant isolates
Species Place of isolation Sxt Te Ctx Caz Sam AmC Am
Healthy people
Haemophilus influenzae (n = 1) Nasopharynx (n = 1) 0 0 0 0 0 0 0
Haemophilus parainfluenzae (n = 65) Nasopharynx (n = 65) 8 (12.3) 4 (6.2) 4 (6.2) 5 (7.7) 3 (4.6) 1 (1.5) 10 (15.4)
Patients with sarcoidosis
Haemophilus influenzae (n = 19) Nasopharynx (n = 6) 1 (16.7) 0 0 0 0 1 (16.7) 0
Sputum (n = 13) 1 (7.7) 2 (15.4) 0 0 0 0 0
Haemophilus parainfluenzae (n = 96) Nasopharynx (n = 47) 10 (21.3) 9 (19.1) 2 (4.3) 3 (6.4) 0 0 6 (12.8)
Sputum (n = 49) 8 (16.3) 6 (12.2) 1 (2.0) 5 (10.2) 0 0 2 (4.1)
Abbreviations: Am ampicillin, AmC amoxycillin/clavulanate, Caz ceftazidime, Ctx cefotaxime, Sam ampicillin-sulbactam, Sxt trimethoprim/sulfametoxazole, Te tetracycline
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was revealed by CLSM image (Fig. 2). The biofilm area
formed by living (Fig. 2a) and dead (Fig. 2c) cells is pre-
sented. The textural parameters were detected as the
grey scale intensity of the biofilm formed by live (Fig. 2b)
and dead (Fig. 2d) cells.
Discussion
Several environmental agents interacting with social and
genetic factors and including immune responses to mi-
crobial components rather than an infection per se have
been considered to play a role in the pathogenesis of sar-
coidosis [1, 2, 4]. In our study changes in the healthy
conditions, in the imaging diagnostics of the chest and
in levels of three major immunoglobulins (IgG, IgM and
IgA) as well as CRP value with respect to sarcoidosis
and the age and gender were shown (Tables 1 and 2).
Similar observations were also done by other authors
[28–31]. Hiperglobulinemia is frequently observed in pa-
tients with sarcoidosis [30]. Changes observed in this
group of patients [29, 30] and in elderly people [31] sug-
gested an association between age, race, sex and the im-
mune system’s defense as well as microbials presence.
According to Buckley et al. [29], in patients with sarcoid-
osis the increase in IgG was significant in white patients,
and the increase in IgM concentration was significant only
in black patients, especially in black woman. Cagatay et al.
[32] found higher than normal laboratory values for im-
munoglobulins IgG, IgA and IgM. They have noted that
IgG and IgA levels were significantly higher in the group
of routinely checked patients without any clinical
Table 5 Distribution of beta-lactamase positive ampicillin-resistant Haemophilus parainfluenzae isolates in patients with sarcoidosis
Biotype Nasopharynx Sputum
Resistance profile (No. of isolates) MICAm (μg/ml) Resistance profile (No. of isolates) MICAm (μg/ml)
I Am (1) 24 AmTe (1) 4
AmSxt (1) >256 AmTe (1) 48
AmCtxCazSxt (1) 8
AmTeSxt (1) 128
III AmCtxCazTeSxt (1) 6
AmTeSxt (1) 6
Abbreviations: Am ampicillin, Caz ceftazidime, Ctx cefotaxime, Te tetracycline, Sxt trimethoprim/sulfametoxazole
Ampicillin breakpoints used for interpretation of minimal inhibitory concentration (MICAm): susceptible ≤1 μg/ml, intermediate = 2 μg/ml and resistant ≥ 4 μg/ml,
according to [25]




OD570 range No. (%) of isolates
Haemophilus influenzae Haemophilus parainfluenzae
Healthy people
Nasopharynx (n = 1) Nasopharynx (n = 65)
Non-producers 0.0 0 (0.0) 8 (12.3)
Weak 0.01–0.24 1 (100) 15 (23.1)
Moderate 0.25–0.48 0 (0.0) 3 (4.6)
Strong 0.49–0.96 0 (0.0) 12 (18.5)
Very strong ≥0.97 0 (0.0) 27 (41.5)
Patients with sarcoidosis
Nasopharynx (n = 4) Sputum (n = 8) Nasopharynx (n = 31) Sputum (n = 26)
Non-producers 0.0 1 (25.0) 3 (37.5) 12 (38.7) 6 (23.1)
Weak 0.01–0.24 3 (75.0) 5 (62.5) 11 (35.5) 9 (34.6)
Moderate 0.25–0.48 0 (0.0) 0 (0.0) 0 (0.0) 3 (11.5)
Strong 0.49–0.96 0 (0.0) 0 (0.0) 1 (3.2) 4 (15.4)
Very strong ≥0.97 0 (0.0) 0 (0.0) 7 (22.6) 4 (15.4)
Distribution of biofilm-producers was detected using the crystal-violet (CV) method. The cut-off OD (ODc; here: 0.1 ± 0.02) was defined as three standard deviations
above the mean OD570 of the negative control. The categories of biofilm-producers: 0 - non-producers (OD ≤ODc); 1, weak (ODc < OD ≤ 2xODc); 2, moderate
(2xODc < OD ≤ 4xODc); 3, strong (4xODc < OD ≤ 8xODc); 4, very strong (8xODc < OD) producers, according to [26]
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Table 7 Morphometric parameters of biofilm formed by Haemophilus influenzae and Haemophilus parainfluenzae isolates taken from
patients with sarcoidosis
Haemophili isolates selected from Thickness of
biofilm ± SD (μm)
Measurement area covered
by biofilm (%) ± SD
Content of live cells (%)
in biofilm ± SD
Biofilm area covered by
live cells (%) ± SD
Haemophilus influenzae
Nasopharynx (n = 3) 11.3 ± 3.2 68.9 ± 2.5 58.4 ± 2.97 66.99 ± 9.1
Sputum (n = 4) 16.4 ± 3.7 73.6 ± 7.96 81.5 ± 5.4 81.4 ± 1.6
All (n = 7) 14.2 ± 3.5 71.6 ± 5.6 71.6 ± 4.4 75.2 ± 4.8
Haemophilus parainfluenzae
Nasopharynx (n = 10) 20.5 ± 4.9 47.1 ± 5.9 76.8 ± 4.2 72.5 ± 12.5
Sputum (n = 8) 19.4 ± 3.7 54.95 ± 3.5 86.0 ± 5.4 84.6 ± 4.7
Total (n = 18) 20.0 ± 4.3 50.58 ± 4.8 80.9 ± 4.8 77.9 ± 8.98
Averages morphometric parameters of biofilm formed by Haemophilus influenzae and Haemophilus parainfluenzae isolates was calculated on the basis of data
assessed using confocal laser scanning microscopy (CLSM) images after 24 h incubation
Fig. 2 Biofilm formed by living and dead cells of Haemophilus parainfluenzae SHpiNP18C strain. Expanations: Biofilm formed by living (a, b) and
dead (c, d) cells of Haemophilus parainfluenzae SHpiNP18C and detected using two-dimensional (2d: a, c) or three-dimensional (3d: b, d) CLSM image
with gray level values varying from 0 to 250 (b, d) after 24 h of incubation. The layer of living cells was located on or between the structures formed
by dead cells. The living and dead cells forming biofilm were detected in the green and red canals, respectively, and the structure of the biofilm was
shown in XZ plan on the basis of 3D scan
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symptoms and during established the activity of the dis-
ease. Drent et al. [33] have identified a high CRP concen-
tration associated with severe fatigue in sarcoidosis.
The human microbiota has multidirectional effects on
the host’s health and changes in its composition may
have important consequences for human pathophysi-
ology and disease development [5, 7, 8, 34]. According
to literature, bacterial 16S rRNA from H. influenzae as
well as Moraxella catarrhalis was detected in sarcoid
fluid samples [35]. Cantwell’s review [3] pointed to the
presence of other bacterial species (e.g. Mycobacterium
spp., staphylococci, Propionibacterium acnes) in the bi-
opsy of sarcoid tissue, blood, and skin samples taken
from patients with sarcoidosis.
According to our results, higher rate of nasopharyn-
geal colonization by H. influenzae, but not by H. parain-
fluenzae (P = 0.05 vs. P = 0.49) was found in patients
with sarcoidosis as compared to colonization in healthy
people. It suggests that sarcoidosis can be regarded as a
factor predisposing for colonization by H. influenzae. Be-
sides, H. influenzae was frequently found in the sputum
samples taken in patients with sarcoidosis even if this
bacterial species was absent in the nasopharynx. In our
opinion, it suggests the role of H. influenzae in the lower
respiratory tract colonization and inflammation particu-
larly in chronic diseases, e.g. in patients with sarcoidosis.
In the literature [36], it has been documented that a
combination of pathogenic mechanisms of bacteria and
defects in host defense may allow this species to their
migration into the lower respiratory tract. This may re-
sult in chronic colonization and/or in acute exacerba-
tions of airway disease.
Despite the high and a similar number of people colo-
nized by H. parainfluenzae in the nasopharynx of
healthy people and patients with sarcoidosis (83.8 % vs.
96.8 %), we observed a decreased number of this species
isolates with different phenotypes, differentiated on the
basis of growth morphology, biochemical characteristics
and biotypes. In 30 patients with sarcoidosis 47 isolates
of H. parainfluenzae were identified, while in 31 healthy
people - 65 isolates of this species. H. parainfluenzae
isolates with biotypes I and II were found to occur most
frequently, similarly in patients with sarcoidosis and in
healthy people (Table 3). As found by other authors
[37–39], these biotypes constituted most of H. parain-
fluenzae isolates in patients with other respiratory dis-
eases such as chronic bronchitis or cystic fibrosis.
During our studies we compared the antimicrobial
susceptibility of nasopharyngeal H. parainfluenzae iso-
lates obtained in patients with sarcoidosis and in healthy
people (Table 4). Resistance of these isolates to tetracyc-
line (P = 0.041) and trimethoprim/sulfametoxazole (P =
0.297) in patients with sarcoidosis was higher compared
to that in healthy people. In contrast, resistance to beta-
lactams (P = 0.214), including ampicillin (P = 1.000) was
lower in patients with sarcoidosis compared to that in
healthy people. These differences may be due to higher
consumption of a given group of antimicrobials in a de-
fined population. The growing antibiotic resistance and
reduction or elimination their effectiveness is one of the
world’s most pressing public health problems [40].
Beta-lactam antibiotics are the most widely used anti-
microbial agents during treatment of both community-
acquired and hospital infections. The resistance to this
group of antimicrobials in Haemophilus spp. usually is
mediated by the production of beta-lactamases and the
presence of altered penicillin-binding protein (PBP) with
lowered affinity for these antibiotics as a target site [17, 41].
The ampicillin-resistant, beta-lactamase positive H. parain-
fluenzae isolates from patients with sarcoidosis were found
in our studies (Tables 4 and 5). This may have some impli-
cations including the possibility to exchange resistance
genes within microorganisms [40–45].
According to literature, over the past years many au-
thors detected beta-lactamases mainly in H. influenzae
and rarely in H. parainfluenzae isolates taken from pa-
tients with respiratory tract infections as well as from
healthy people [25, 26, 46]. It was shown that DNA mu-
tation and rapid multiplication as well as transformation
can be important mechanisms in the spread of drug re-
sistance in haemophili, including the ampicillin resist-
ance due to beta-lactamase production [45, 46]. It seems
that especially efficient in transformation were H. para-
influenzae cells with a highest ability to develop compe-
tence and transfer of resistance genes occurs via free
DNA (from dead or lysed cells) during natural trans-
formation from the medium by competent cells. It may
explain the acquisition of resistance or resistance gene
exchange with other microorganisms. Besides, resistance
and reduced susceptibility to beta-lactams mediated by
altered PBPs is also important in many bacterial patho-
gens, including beta-lactamase negative H. influenzae
[47]. For this reason, there are different events that may
contribute to the emerge of resistance: the acquisition of
resistance genes (e.g. beta-lactamases) by conjugation or
transformation; and inter-species recombination of the
ftsI gene [47, 48]. According to Gromkova et al. [46],
most efficient in transformation among H. parainfluen-
zae strains was biotype II, followed by biotype I.
It was shown in this paper that H. parainfluenzae iso-
lates selected in patients with sarcoidosis compared to
isolates selected in healthy people had a lower ability for
biofilm production (Table 6). It is possible that a reduction
in the number of H. parainfluenzae strains capable of
biofilm formation may contribute to an increased
colonization by certain opportunistic pathogens like H.
influenzae (the present results) or by other bacteria [3, 4].
The CLSM technique revealed that biofilms formed in
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vitro by H. parainfluenzae and H. influenzae isolates taken
from patients with sarcoidosis (Table 7, Fig. 2) had high
content of live cells (average 72 to 81 %), suggesting the
possibility of bacterial persistence and dispersal in vivo.
Biofilm may be regarded as a pathogenic or protective
factor depending on the conditions [18, 21]. Nontype-
able H. influenzae [NTHi] biofilms were observed for
both bacteria colonizing the tissue of human, as an etio-
logic agent which causes the infection or exacerbation of
chronic respiratory diseases [49–51]. On the other hand,
Clancy and Dunkley [52] showed that oral NTHi could
enhance the mucosal protection and prevent exacerba-
tions of a chronic obstructive pulmonary disease.
On the basis of our results we propose, that haemophili,
mainly H. influenzae and H. parainfluenzae, would be mi-
croorganisms indicative in respiratory microbiota changes
as well as healthy condition in patients with chronic dis-
eases. We observed higher frequency of H. influenzae
colonization in patients with sarcoidosis compared to
healthy people (P = 0.05). All H. influenzae isolates were
weak- or non-biofilm producers independently to source of
isolation and peoples’ health condition. Moreover, despite
the high prevalence of H. parainfluenzae in the nasophar-
ynx of people from both studied groups (P = 0.49), less
number of isolates of this species obtained in nasopharyn-
geal samples in patients with sarcoidosis as compared to
healthy people were classified as biofilm-producers (61.3 %
vs. 87.7 %, P = 0.006), especially as strong and very strong
biofilm-producers (25.8 % vs. 60 %, P = 0.002).
Conclusions
The obtained results suggest that sarcoidosis, associated
with many different factors, may be partially due to the re-
spiratory microbiota condition. This is the first study de-
scribing qualitative and quantitative changes in the
respiratory microbiota in patients with sarcoidosis with
the respect to H. influenzae and H. parainfluenzae bio-
types and their ability for biofilm formation. The question
whether the biofilm formed by these bacterial species is a
causative or just a protective factor in recurrent or chronic
diseases, e.g. sarcoidosis, requires further studies.
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